Latest total liabilities for GTBP: $2.4M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), GTBP shows a total liabilities of $2.4M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GTBP's total liabilities is now $2.4M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether GT Biopharma is outperforming or lagging.
Tracking GTBP's total liabilities over time shows whether GT Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has GT Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $2.4M) with ownership activity and broader fundamentals.
GT Biopharma's total liabilities is $2.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.